Biome Australia (ASX:BIO)
ASX announcement history & article coverage
Transparent by design.
Announcments by Biome Australia (ASX:BIO) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
FY26 Trading Update
Biome Australia reports record $23.9m FY26 sales, 30% growth, on track for Vision 27 targets
Change of Director's Interest Notice
Change of Director's Interest Notice
Ceasing to be a substantial holder
Change of Director's Interest Notice
Change of Director's Interest Notice
Biome Signs Australian Manufacturing Agreement
Biome Australia to Onshore Activated Probiotics Production with SPA, Targeting Margin and Working Capital Gains
Biome Investor Presentation June 2026
Investor Webinar
BMB18 clinical trial expands to dual site
Biome Australia launches international multi-centre clinical trial for proprietary probiotic BMB18
Probiotical Exclusive Supply Agreement Extended
Biome extends exclusive supply deal with Probiotical to 2028, supporting international expansion
Change of Director's Interest Notice
Change of Director's Interest Notice
Revised Appendix 4C Quarterly Cash Flow Report
Quarterly Activities & Cashflow Report
Biome Australia hits 1 million probiotic boxes sold, expands internationally, and expects FY26 profit
Patent Application Filed for Probiotic Strain BMB18
Biome Files Patent for Next Gen Probiotic BMB18, Clinical Trial to Start Q4 FY26